The Clinical Efficacy of R-CHOP Chemotherapy in Patients with Previously Untreated Diffuse Large B-cell Lymphoma / 대한혈액학회지
Korean Journal of Hematology
;
: 59-65, 2004.
Article
in Korean
| WPRIM
| ID: wpr-720088
ABSTRACT
BACKGROUND:
In combination with standard-dose CHOP (cyclophosphamide, vincristine, adriamycin, and prednisolone), the addition of rituximab produces a better clinical response in the treatment of aggressive B-cell non-Hodgkin's lymphoma (NHL) than CHOP alone.METHODS:
Thirty-four patients with previously untreated diffuse large B-cell NHL received at least three or four cycles of rituximab 375 mg/m2 or 500 mg per dose on day 1 of each cycle in combination with CHOP chemotherapy.RESULTS:
The median age of patients were 61.5 years (range, 28-83 years). After the end of therapy, twenty-five patients (73.5%) experienced a complete response, four patients (11.8 %) had a partial response, and two patients (5.9%) were classified as having progressive disease. The median follow-up duration was 9.4 months (range, 0.2-19.5 months) and 1-year overall survival and progression free survival was 84.8+/-8.7% and 80.3+/-9.4%, respectively. Two patients (5.9%) experienced fever, myalgia, and skin eruption due to rituximab. Neutropenia of grade 3 or 4 occurred in thirty-one patients (91.2%).CONCLUSION:
The benefits of rituximab in combination with CHOP chemotherapy include high response rates and good tolerance. However, further prospective, randomized studies are needed to draw definitive conclusions.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Skin
/
Vincristine
/
Lymphoma, Non-Hodgkin
/
B-Lymphocytes
/
Doxorubicin
/
Follow-Up Studies
/
Lymphoma, B-Cell
/
Disease-Free Survival
/
Drug Therapy
/
Fever
Type of study:
Controlled clinical trial
/
Observational study
/
Prognostic study
Limits:
Humans
Language:
Korean
Journal:
Korean Journal of Hematology
Year:
2004
Type:
Article
Similar
MEDLINE
...
LILACS
LIS